http://www.onclive.com/web-exclusives/fda-approves-nivolumab-for-hepatocellular-carcinoma
Apparently this is huge for the HCC space. Sorafenib had now single digit response rates vs high teens for this new drug. Its got the sector in a bit of a buzz.